title: Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus.
abstract: Intravenous immunoglobulin (IVIg) is used for replacement therapy in immunodeficiency states and for immunomodulation of various autoimmune diseases. Several case reports and series support a beneficial role of IVIg in systemic lupus erythematosus (SLE), both as salvage immunotherapy and in control of disease activity in general and amelioration of classical disease manifestations. Further, lupus nephritis can also be treated usually successfully with IVIg. A few questions remain unanswered as to the appropriate therapeutic dosage and the clinical manifestations that can be best treated with IVIg.
authors.affiliation: Department of Medicine 'B' & Center for Autoimmune Diseases, Sheba Medical Center Tel-Hashomer, Israel.
authors.forename: Yaniv
authors.initials: Y
authors.lastname: Sherer
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D005921:Glomerulonephritis / Q000188:drug therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008181:Lupus Nephritis / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous